BMAA companion diagnostic - SemaThera
Alternative Names: BMAA companion diagnostic - SemaThera/Chiome Bioscience; SEMA3A mAb companion diagnostic - SemaTheraLatest Information Update: 28 Sep 2022
At a glance
- Originator SemaThera
- Developer Chiome Bioscience; SemaThera
- Class Antibody diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic macular oedema; Diabetic nephropathies
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Diabetic-macular-oedema(Diagnosis) in Canada
- 28 Sep 2022 No recent reports of development identified for research development in Diabetic-nephropathies(Diagnosis) in Canada